Ustekinumab in the management of Crohn’s disease: Expert opinion-Reference-Cited by-同舟云学术

Ustekinumab in the management of Crohn’s disease: Expert opinion

Published:2018-07 Issue:7 Volume:50 Page:653-660
ISSN:1590-8658
Container-title:Digestive and Liver Disease
language:en
Short-container-title:Digestive and Liver Disease

Author:

Armuzzi Alessandro,Ardizzone Sandro,Biancone Livia,Castiglione Fabiana,Danese Silvio,Gionchetti Paolo,Orlando Ambrogio,Rizzello Fernando,Scribano Maria Lia,Vecchi Maurizio,Daperno Marco

Funder

AbbVie

Janssen Pharmaceuticals

Janssen Biotech

Biogen

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference67 articles.

1. Epidemiology and natural history of inflammatory bowel diseases;Cosnes;Gastroenterology,2011

2. Genetic origin of IBD;Hugot;Inflamm Bowel Dis,2004

3. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics;Shanahan;Gastroenterology,2001

4. Immune dysfunction in inflammatory bowel disease;Neuman;Transl Res,2007

5. Neuroimmunology of the gut: physiology, pathology, and pharmacology;Ben-Horin;Curr Opin Pharmacol,2008

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical use of biologics for Crohn’s disease in adults: lessons learned from real-world studies;Expert Opinion on Biological Therapy;2024-02-23

2. Research progress of Ustekinumab in the treatment of inflammatory bowel disease;Frontiers in Immunology;2024-02-22

3. Clinical Outcomes of Ustekinumab in Inflammatory Bowel Disease;Cureus;2023-10-11

4. Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology;Digestive and Liver Disease;2023-04

5. Biomarkers in Inflammatory Bowel Diseases: Predicting the Indication and the Effect of Biologics;Journal of Gastrointestinal and Liver Diseases;2022-06-12